EpiVax
EpiVax is a Providence, Rhode Island-based biotechnology company specializing in immunogenicity risk assessment for biologics and vaccines.
Profile
Predicts and reduces unwanted immune reactions to biologic drugs and vaccines using computational and lab testing methods.
EpiVax is a Providence, Rhode Island-based biotechnology company specializing in immunogenicity risk assessment for biologics and vaccines. Founded in 1998 by Anne De Groot and Bill Martin, the company has evolved from academic roots into a commercial entity serving pharmaceutical developers. Its core offering combines computational immunoinformatics tools with wet-lab assays to predict and mitigate unwanted immune responses to therapeutic proteins, peptides, and gene therapies.
In 2025, EpiVax expanded its leadership team with the appointments of Vibha Jawa as Chief Scientific Officer and Guilhem Richard as Chief Technology Officer, signaling a push into AI-driven immunogenicity prediction and personalized cancer vaccines. The company collaborates extensively with regulatory agencies, including an FDA-contracted study on peptide impurities in generic teriparatide published in December 2025. While financials are not publicly disclosed, EpiVax serves 18 of the top 20 pharmaceutical companies and has analyzed over 13 million sequences to date. Its 2026 acquisition by SV Health Investors marked a transition to accelerated growth in computational immunology services.
Who buys this
- Pharmaceutical companies developing biologic drugs
- Biotech firms working on gene therapies and vaccines
- Generic drug manufacturers assessing peptide impurities
- Academic researchers in immunology
- Government agencies like FDA requiring immunogenicity assessments
Strengths and what to watch
Strengths
- Published collaboration with FDA scientists on peptide impurity risk assessment (Frontiers in Immunology 2025)
- Proprietary ISPRI™ platform with 28 years of refinement in epitope prediction
- AI-driven ADA prediction model launched in 2025 for monoclonal antibodies
Watch for
- Dependence on pharmaceutical R&D budgets which face cyclical pressures
- Competition from larger CROs expanding immunogenicity service offerings
- Unproven commercial traction for Ancer® cancer vaccine platform despite technical advancements
Recent moves
Key Information
- Founded
- 1998
- Employees
- 49
- Headquarters
- Providence, Rhode Island
- Country
- United States
Frequently Asked Questions
What does EpiVax do?
EpiVax specializes in predicting and reducing unwanted immune reactions to biologic drugs and vaccines. Using computational immunoinformatics and lab testing, they assess immunogenicity risks for therapeutic proteins, peptides, and gene therapies. Their services help pharmaceutical developers create safer treatments with fewer adverse immune responses.
How does EpiVax predict immune reactions to drugs?
EpiVax combines computational tools like their ISPRI™ platform with wet-lab assays to analyze immune responses. Their 28-year refined system evaluates protein sequences to identify potential immunogenic hotspots. In 2025, they introduced AI-driven models for more accurate antibody response predictions in biologic therapies.
Has EpiVax worked with the FDA?
Yes, EpiVax collaborated with FDA scientists on a 2025 study about peptide-related impurities in generic teriparatide. Published in Frontiers in Immunology, this research helps establish standards for assessing immunogenicity risks in generic biologic drugs entering the market.
Who uses EpiVax's services?
EpiVax serves 18 of the top 20 pharmaceutical companies, plus biotech firms developing gene therapies, generic drug manufacturers assessing impurities, academic researchers, and regulatory agencies. Their immunogenicity assessments are critical for bringing safer biologic treatments and vaccines to market.
What's new with EpiVax's technology?
In 2025, EpiVax launched an AI-driven ADA prediction model for monoclonal antibodies and expanded leadership with new CSO and CTO appointments. Their Ancer® cancer vaccine platform represents ongoing innovation, though commercial adoption in personalized cancer vaccines remains in early stages.
How established is EpiVax in immunology?
Founded in 1998, EpiVax has analyzed over 13 million sequences and refined their ISPRI™ platform for 28 years. The 2026 acquisition by SV Health Investors marked their transition from academic roots to commercial growth in computational immunology services for global pharmaceutical developers.
Sources
- www.prnewswire.com — FDA collaboration on peptide impurities study
- epivax.com — 2025 company milestones and leadership appointments
- www.epivax.com — Company overview and product offerings
- epivax.com — Historical development of iVAX toolkit